For those pushing beyond average gains, the CrazyBulk Growth Hormone Stack is engineered for elite-level performance and ...

I’m excited to now have a highly effective therapy for a broad range of patients living with C3G and primary IC-MPGN,” said ...

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company, focused on developing novel ...

Regional Health Properties, Inc., a Georgia corporation, is a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term care ...

About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare ...

SonderCare, a leading manufacturer of home-based hospital beds, today announced expanded access to its certified premium home care beds to meet growing demand from the “missing middle”—the estimated ...

The live webcast will be accessible under the Events & Presentations section of the AVITA Medical website at ir.avitamedical.com. To participate by telephone, please register in advance to receive ...

Jefferies, TD Cowen and Leerink Partners are acting as joint book-running managers for the Convertible Notes Offering and the Common Stock Offering. LifeSci Capital is acting as lead manager for the ...

Findings from breakthrough approach to early detection for Alzheimer’s disease (AD) has the potential to reduce time from earliest development of symptoms to care by 4.5 years are presented at the ...

The Company intends to use the net proceeds from the Offering to pay $1,500,000 for marketing and advertising services to be provided by IR Agency LLC, $1,000,000 to fund the initial milestone payment ...

Nyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine ...

Dyne also reported new positive long-term data from adult DM1 patients enrolled in the randomized, placebo-controlled multiple ascending dose (MAD) portion of the DYNE-101 ACHIEVE trial, including ...